Company intelligence / Profile preview

Olmafarm

Ownership: Private
Development stage: Other

Overview

Olmafarm is a Russian pharmaceutical company specializing in the development and production of immunomodulatory and antiviral medications. The company is best known for its proprietary drug, Gepon, a synthetic 14-amino acid peptide that stimulates the production of alpha and beta interferons and activates natural killer cells. Olmafarm focuses on treating complex infections, including HIV/AIDS, viral hepatitis, and chronic mucosal diseases. Their operations include research, clinical development, and manufacturing of peptide-based therapeutics. The company is headquartered in Moscow and primarily serves the Russian and CIS markets.

Therapeutic areas: GastroenterologyInfectious Diseases
Modalities: Peptides
Industry: Biotech

Beyond the preview

Go deeper on Olmafarm.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Olmafarm.

Explore the full profile